Abstract
For successful treatment of cancer patients, it is crucial to identify subgroups that respond to certain types of targeted therapy. A key element for tumor growth is the abundance of receptors and binding of growth factors, which can be diminished via therapeutic antibodies. Here, a mechanistic signaling network model is linked to patient-specific ribonucleic acid sequencing data (RNAseq), enabling the prediction of individuals susceptible to a particular medication. The mechanistic model comprises multiple receptors and their dimerization, and is calibrated using time-resolved in-vitro data. Further, the model is combined with in-vitro cell viability measurements via a machine learning algorithm and ultimately applied to patient-derived data to predict ligand dependence of tumors. For this purpose, RNA sequencing data are exploited to constrain model parameters and generalize model response. Mathematical modeling of signal transduction is used as a mediator, performing a non-trivial transformation of initial protein expression levels and ligand conditions to cell-type specific response. Thereby, it allows for bridging the gap between studies of signal transduction on a short time scale and cell fate decisions in the long term, potentially aiding in drug development, patient stratification, and prediction of tumor response. This chapter is based on work previously published in Hass et al. (NPJ Syst Biol Appl 3(1):27, 2017) and Hass (Quantifying cell biology: mechanistic dynamic modeling of receptor crosstalk. PhD thesis, Albert-Ludwigs-Universität Freiburg, 2017).
Keywords
References
Adlung L, Kar S, Wagner MC, She B, Chakraborty S, Bao J, Lattermann S, Boerries M, Busch H, Wuchter P, Ho AD, Timmer J, Schilling M, Höfer T, Klingmüller U (2017) Protein abundance of AKT and ERK pathway components governs cell type-specific regulation of proliferation. Mol Syst Biol 13(1):904
Altman RB (2015) Predicting cancer drug response: advancing the DREAM. Cancer Discov 5(3):237–238
Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(suppl 4):31–39
Arteaga CL, Engelman JA (2014) ErbB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25(3):282–303
ATLAS Collaboration (2015) Evidence for the Higgs-boson Yukawa coupling to tau leptons with the ATLAS detector. J High Energy Phys 2015(4):117
Bansal M, Yang J, Karan C, Menden MP, Costello JC, Tang H, Xiao G, Li Y, Allen J, Zhong R, Chen B, Kim M, Wang T, Heiser LM, Realubit R, Mattioli M, Alvarez MJ, Shen Y, Community ND, Gallahan D, Singer D, Saez-Rodriguez J, Xie Y, Stolovitzky G, Califano A (2014) A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol 32(12):1213–1222
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603–607
Basilico C, Arnesano A, Galluzzo M, Comoglio PM, Michieli P (2008) A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of MET. J Biol Chem 283(30):21267–21277
Breiman L, Friedman JH, Olshen RA, Stone CJ (1984) Classification and regression trees, vol 19. CRC, Boca Raton
Chong CR, Jänne Pa (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19(11):1389–1400
Citri A, Yarden Y (2006) EGF-ErbB signalling: towards the systems level. Nat Rev Mol Cell Biol 7(7):505–516
Coleman T, Li Y (1996) An interior, trust region approach for nonlinear minimization subject to bounds. SIAM J Optim 6:418–445
Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, Bansal M, Ammad-Ud-Din M, Hintsanen P, Khan Sa, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G (2014) A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol 32(12):1–103
Endo H, Okuyama H, Ohue M, Inoue M (2014) Dormancy of cancer cells with suppression of AKT activity contributes to survival in chronic hypoxia. PLoS ONE 9(6):e98858
Engelman Ja, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne Pa (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ErbB3 signaling. Science 316(5827):1039–1043
FDA (2015) Accelerating the development of new pharmaceutical therapies. Technical report, US Food and Drug Administration
Fisher RA (1912) On an absolute criterion for fitting frequency curves. Messenger Math 41:155–160
Gazdar AF, Shigematsu H, Herz J, Minna JD (2004) Mutations and addiction to EGFR: The Achilles ‘heal’ of lung cancers? Trends Mol Med 10(10):481–486
Hannah R, Beck M, Moravec R, Riss T (2001) CellTiter-Glo™ Luminescent cell viability assay: a sensitive and rapid method for determining cell viability. Promega Cell Notes 2:11–13
Hass H (2017) Quantifying cell biology: Mechanistic dynamic modeling of receptor crosstalk. PhD thesis, Albert-Ludwigs-Universität Freiburg
Hass H, Masson K, Wohlgemuth S, Paragas V, Allen JE, Sevecka M, Pace E, Timmer J, Stelling J, MacBeath G, Schoeberl B, Raue A (2017) Predicting ligand-dependent tumors from multi-dimensional signaling features. NPJ Syst Biol Appl 3(1):27
Heinrich R, Neel BG, Rapoport TA (2002) Mathematical models of protein kinase signal transduction. Mol Cell 9(5):957–970
Hill SM, Heiser LM, Cokelaer T, Unger M, Nesser NK, Carlin DE, Zhang Y, Sokolov A, Paull EO, Wong CK, Graim K, Bivol A, Wang H, Zhu F, Afsari B, Danilova LV, Favorov AV, Lee WS, Taylor D, Hu CW, Long BL, Noren DP, Bisberg AJ, HPN-DREAM Consortium, Mills GB, Gray JW, Kellen M, Norman T, Friend S, Qutub AA, Fertig EJ, Guan Y, Song M, Stuart JM, Spellman PT, Koeppl H, Stolovitzky G, Saez-Rodriguez J, Mukherjee S (2016) Inferring causal molecular networks: empirical assessment through a community-based effort. Nat Methods 13(4):310–318
Hindmarsh AC, Brown PN, Grant KE, Lee SL, Serban R, Shumaker DE, Woodward CS (2005) SUNDIALS: suite of nonlinear and differential/algebraic equation solvers. ACM Trans Math Softw 31(3):363–396
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13(10):714–726
Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D, Chen H, Feuer E, Cronin Ke (2016) SEER cancer statistics review, 1975–2013. Technical report, National Cancer Institute, Bethesda
Jin Q, Esteva FJ (2008) Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13(4):485–498
Kaushansky A, Allen JE, Gordus A, Stiffler MA, Karp ES, Chang BH, MacBeath G (2010) Quantifying protein-protein interactions in high throughput using protein domain microarrays. Nat Protoc 5(4):773–790
Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM, Fitzgerald JB, Nielsen UB, Wolf BB (2015) Enhanced targeting of the EGFR network with MM-151, an oligoclonal anti-EGFR antibody therapeutic. Mol Cancer Ther 14(7):1625–1636
Kholodenko B (2006) Cell-signalling dynamics in time and space. Natl Rev Mol Cell Biology 7(3):165–176
Kholodenko BN, Demin OV, Moehren G, Hoek JB (1999) Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem 274(42):30169–30181
Kitano H (2002) Systems biology: a brief overview. Science 295(5560):1662–1664
Knight-Schrijver V, Chelliah V, Cucurull-Sanchez L, Le Novère N (2016) The promises of quantitative systems pharmacology modelling for drug development. Comput Struct Biotechnol J 14:363–370
Kreutz C, Rodriguez MMB, Maiwald T, Seidl M, Blum HE, Mohr L, Timmer J (2007) An error model for protein quantification. Bioinformatics 23(20):2747–2753
Kris M, Natale R, Herbst R, Lynch TJ, Prager D, Belani J, Schiller J, Kelly K, Spiridonidis H, Sandler A, Albain K (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial. J Am Med Assoc 290(16):2149–2158
Lai AZ, Abella JV, Park M (2009) Crosstalk in MET receptor oncogenesis. Trends Cell Biology 19(10):542–551
Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274–293
Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27(35):5924–5930
Ledford H (2011) Ways to fix the clinical trial. Nature 477:526–528
Liu F, Wang L, Perna F, Nimer SD (2016) Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nat Rev Cancer 16(6):359–372
Luey BC, May FEB (2016) Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway. Mol Cancer 15(1):8
Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136(5):823–837
Lyashenko E, Niepel M, Dixit P, Lim SK, Sorger P, Vitkup D (2017) Receptor-based mechanism of relative sensing in mammalian signaling networks. bioRxiv https://doi.org/10.1101/158774
Macdonald-Obermann JL, Pike LJ (2014) Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation. J Biol Chem 289(38):26178–26188
Magnuson B, Ekim B, Fingar DC (2012) Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441(1):1–21
Maher KJ, Fletcher MA (2005) Quantitative flow cytometry in the clinical laboratory. Clin Appl Immunol Rev 5(6):353–372
Maiwald T, Hass H, Steiert B, Vanlier J, Engesser R, Raue A, Kipkeew F, Bock HH, Kaschek D, Kreutz C, Timmer J (2016) Driving the model to its limit: profile likelihood based model reduction. PLoS ONE 11(9):e0162366
Marshall C (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80(2):179–185
Masuda H, Zhang D (2012) Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136(2):1–21
Menden MP, Iorio F, Garnett M, McDermott U, Benes CH, Ballester PJ, Saez-Rodriguez J (2013) Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS ONE 8(4):e61318
Mendoza MC, Er EE, Blenis J (2011) The RAS-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36(6):320–328
Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti–EGFR treatment in colorectal cancer: a cohort study. Lancet Oncology 6(5):279–286
Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5(7):621–628
Mullard A (2015) 2014 FDA drug approvals. Nature 14(2):77–81
Nelson MR, Johnson T, Warren L, Hughes AR, Chissoe SL, Xu CF, Waterworth DM (2016) The genetics of drug efficacy: opportunities and challenges. Nat Rev Genet 17(4):197–206
Niepel M, Hafner M, Pace EA, Chung M, Chai DH, Zhou L, Schoeberl B, Sorger PK (2013) Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci Signal 6(294):ra84
Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 1:2005.0010
Organ SL, Tsao MS (2011) An overview of the c-MET signaling pathway. Ther Adv Medl Oncol 3(1):S7–S19
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–500
Peterson M, Riggs M (2015) FDA advisory meeting clinical pharmacology review utilizes a quantitative systems pharmacology (QSP) model: a watershed moment? Pharmacometrics Syst Pharmacol 4(3):189–192
Radivojac P, Clark WT, Oron TR, Schnoes AM, Wittkop T, Sokolov A, Graim K, Funk C, Verspoor K, Ben-Hur A, Pandey G, Yunes JM (2013) A large-scale evaluation of computational protein function prediction. Nat Methods 10(3):221–227
Raman DV, Anderson J, Papachristodoulou A (2017) Delineating parameter unidentifiabilities in complex models. Phys Rev E 95(3):032314
Raue A, Schilling M, Bachmann J, Matteson A, Schelker M, Kaschek D, Hug S, Kreutz C, Harms BD, Theis FJ et al (2013) Lessons learned from quantitative dynamical modeling in systems biology. PLoS ONE 8(9):e74335
Raue A, Steiert B, Schelker M, Kreutz C, Maiwald T, Hass H, Vanlier J, Tönsing C, Adlung L, Engesser R et al (2015) Data2dynamics: a modeling environment tailored to parameter estimation in dynamical systems. Bioinformatics 31(21):3558–3560
Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung L, Chen Y, Huang X, Chan HM, Zhao P, Luk J, Vande Woude G, Wong J (2005) Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res 11(17):6190–6197
Rosenblatt M, Timmer J, Kaschek D (2016) Customized steady-state constraints for parameter estimation in non-linear ordinary differential equation models. Front Cell Dev Biol 4(41)
Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, Anderson RN, Ma J, Ly KN, Cronin KA, Penberthy L, Kohler BA (2016) Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer 122(9):1312–1337
Schapire RE (1990) The strength of weak learnability. Mach. Learn. 5(2):197–227
Schoeberl B, Pace E, Howard S, Garantcharova V, Kudla A, Sorger PK, Nielsen UB (2006) A data-driven computational model of the ErbB receptor signaling network. In: Annual international conference of the IEEE engineering in medicine and biology - proceedings, pp 53–54
Schoeberl B, Pace Ea, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra AV, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West Ka, Leszczyniecka M, Feldhaus MJ, Kudla AJ, Nielsen UB (2009) Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2(77):ra31
Schoeberl B, Kudla A, Masson K, Kalra A, Curley M, Finn G, Pace E, Harms B, Kim J, Kearns J, Fulgham A, Burenkova O, Grantcharova V, Yarar D, Paragas V, Fitzgerald J, Wainszelbaum M, West K, Mathews S, Nering R, Adiwijaya B, Garcia G, Kubasek B, Moyo V, Czibere A, Nielsen UB, MacBeath G (2017) Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121). NPJ Syst Biol Appl 3:16034
Schumacher R, Mosthaf L, Schlessinger J, Brandenburg D, Ullrich A (1991) Insulin and insulin-like growth factor-1 binding specificity is determined by distinct regions of their cognate receptors. J Biol Chem 266(29):19288–19295
Sevecka M, MacBeath G (2006) State-based discovery: a multidimensional screen for small-molecule modulators of EGF signaling. Nat Methods 3(10):825–831
Sevecka M, Wolf-Yadlin A, MacBeath G (2011) Lysate microarrays enable high-throughput, quantitative investigations of cellular signaling. Mol Cell Proteomics 10(4):M110.005363
Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169–181
Shi T, Niepel M, McDermott JE, Gao Y, Nicora CD, Chrisler WB, Markillie LM, Petyuk VA, Smith RD, Rodland KD et al (2016) Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway. Sci Signal 9(436):rs6
Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, Di Fiore PP, Polo S (2005) Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA 102(8):2760–2765
Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL (1994) Coexpression of ErbB2 and ErbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269(20):14661–14665
Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K (1990) Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 50(21):7077–7080
Umekita Y, Ohi Y, Sagara Y, Yoshida H (2000) Co-expression of epidermal growth factor receptor and transforming growth factor-α predicts worse prognosis in breast-cancer patients. Int J Cancer 89(6):484–487
Wilson TR, Longley DB, Johnston PG (2006) Chemoresistance in solid tumours. Ann Oncol 17(10):x315
Würth R, Thellung S, Bajetto A, Mazzanti M, Florio T, Barbieri F (2016) Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. Drug Discov Today 21(1):190–199
Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:3–8
Yarden Y, Pines G (2012) The ErbB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 12(8):553–563
Zahreddine H, Borden K (2013) Mechanisms and insights into drug resistance in cancer. Front Pharmacol 4:28
Acknowledgements
We thank Tim Heinemann, Jeffrey Kearns, Sergio Iadevaia, Yasmin Hasham-bhoy-Ramsay, and Tim Maiwald for their constructive feedback and proof reading the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Hass, H., Raue, A. (2018). Predicting Tumor Growth and Ligand Dependence from mRNA by Combining Machine Learning with Mechanistic Modeling. In: Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1007/7653_2018_29
Download citation
DOI: https://doi.org/10.1007/7653_2018_29
Published:
Publisher Name: Humana Press